Syngene International Ltd. · NSE:SYNGENE
Syngene International — Investor Presentation (September 2025)
17 slides from Syngene International's investor presentation, Sep 9, 2025

Slide 1: Investor Presentation cover letter to stock exchanges
Ref: Syn/CS/SE/IP/2025-26/Sept/05 Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099, Karnataka, India. T +91 80 6891 8000 F +91 80 6891 8808 CIN: L85110KA1993PLC014937 www.syngeneintl.com September 09, 202

Slide 2: Unit-3 plant visit for Investors – 9th September 2025
Unit-3 plant visit for Investors – 9th September 2025

Slide 3: Agenda
Agenda Sr. no Timing Particulars Led by Deepak Jain (CFO) I 11:30 AM – 12:15 PM Tea + Brief Introduction (PPT) of the facility Himanshu Saxena (Head, Biologics manufacturing) Himanshu Saxena ( Head, Biologics manufacturing) Mr. Nainesh Dwivedi (Head, Quality for Unit-3) • Divide participant in 2 gro

Slide 4: Syngene Management & Leadership for Unit-3 visit
Syngene Management & Leadership for Unit-3 visit Himanshu Saxena Peter Bains Deepak Jain Head, Managing Director & CEO Chief Financial Officer Biologics Manufacturing • MD & CEO, Syngene International with over • CFO, Syngene International with over 25 years • Over two decades of expertise in supply

Slide 5: Introduction and overview of facility
01 Introduction and overview of facility Putting Science to Work Putting Science to Work

Slide 6: Background – acquired multimodal biologics facility from Stelis Biopharma
Background – acquired multimodal biologics facility from Stelis Biopharma with integrated drug substance and commercial DP capability in Dec 2023 Strengthens Syngene’s position in the fastest growing Why we acquired 250 segment of the global CRDMO market Market size* (USD bn) Immediate capacity addi

Slide 7: Guidance given at time of acquisition. We are maintaining the guidance for now
Guidance given at time of acquisition. We are maintaining the guidance for now Asset turnover of 1x in less than 5 years $75m acquisition price $10m modification capex (Acquisition concluded at gross value of Rs 617 (INR 100 Crores to repurpose and $85m to operationalise crores. Value buy as company

Slide 8: Current update and strategic focus
Current update and strategic focus - the facility was part capitalized in Q1 FY26. Focus is to drive integrated projects across human and animal health Where are we now Strategic focus Received local regulatory approvals in May 2025 Focus on building pipeline across human health and animal health Pa

Slide 9: Bird’s Eye View of Syngene Unit-3
Bird’s Eye View of Syngene Unit-3 Salient features of the multi modal facility comprising end to end DS and DP manufacturing capability • Drug Substance (DS) : • 8 KL (4*2 KL) commissioned • Feasibility for perfusion • Drug Product (DP) : • Commercial scale, high speed, fill-finish unit • 2 integrat

Slide 10: Integration Journey: Acquisition to Operation in 7 Months
Integration Journey: Acquisition to Operation in 7 Months Operations Q1 FY26 Production Part of Unit-3 facility became operational in Q1 FY26 Equipment July 2024 Delivered a GMP clinical batch Qualification and Area Qualification 15th July test batch initiated of drug substance for a US based Facili

Slide 11: Unit-3 (SU3) Site Master Plan
Unit – 3 (SU3) Site Master Plan Area Details ETP Plot area 22,000 m2 (5.4 Acres) Block-3 200L DS,DP, QC Block Name Utility Block -2 Block-2 2,000L DS + 2,000L DS Expansion Block 1 Expansion Area available 2 Floors (Ground Floor+ First Floor) Block 2 - DS Block First floor (2 wings of 10 KL capacity

Slide 12: Site visit to DS / Utilities
02 Site visit to DS / Utilities Putting Science to Work Putting Science to Work

Slide 13: Site visit – protocols
Site visit – protocols • Clothing: Minimum Gowning, Head cap & Shoe cover • Decorum to be maintained while visiting labs • Please limit Q&A with the technical teams related to infrastructure, technical/plant details etc. • We will have a separate Q&A/feedback session with Peter and Deepak to cover s

Slide 14: Lunch
03 Lunch Putting Science to Work Putting Science to Work

Slide 15: Feedback/Q&A
04 Feedback/Q&A Putting Science to Work Putting Science to Work

Slide 16: Feedback/ Q&A
Feedback/ Q&A • Feedback/thoughts on the site, capabilities, infrastructure from investors • Open Q&A Putting Science to Work 15

Slide 17: Thank you
Thank you © 2025 Syngene International Limited, Bengaluru, India. All Rights Reserved. Syngene believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Syngene acknowledges the proprietary rights of other companies to the
Source: NSE filing, Sep 9, 2025
More decks from Syngene International Ltd.
Q2 FY27 Earnings Presentation13 slides · Oct 28, 2026
Q2 FY27 Earnings Presentation32 slides · Oct 27, 2026
Q1 FY27 Earnings Presentation12 slides · Jul 30, 2026
Q1 FY27 Earnings Presentation32 slides · Jul 29, 2026
Q1 FY27 Earnings Presentation31 slides · July 2026
Q4 FY26 Earnings Presentation32 slides · Apr 30, 2026